Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 5/2020

Open Access 01-10-2020 | Dermatomyositis | Case Report

Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2

Authors: Miao Miao, Yuhui Li, Bo Huang, Jing He, Zhanguo Li

Published in: Dermatology and Therapy | Issue 5/2020

Login to get access

Abstract

Hypomyopathic dermatomyositis (DM) presents with cutaneous lesions consistent with dermatomyositis but in the absence of clinically appreciable muscle weakness. The cutaneous manifestations are often refractory and more resistant to conventional therapy than concomitant muscle involvement. We present a 61-year-old hypomyopathic patient with DM who failed to respond to standard therapy but was successfully treated by low-dose interleukin-2 (IL-2) with no significant side effects. We conclude that low-dose IL-2 is a safe and effective treatment for hypomyopathic DM.
Literature
1.
2.
Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single. Open Clin Trial Ann Rheum Dis. 2019;78(2):209–17.CrossRef
3.
Feng M, Guo H, Zhang C, et al. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. Int Immunopharmacol. 2019;77:105912.CrossRef
4.
Vuong V, Duong TA, Aouizerate J, et al. Dermatomyositis: factors predicting relapse. J Eur Acad Dermatol Venereol. 2016;30(5):813–8.CrossRef
5.
Wolstencroft PW, Chung L, Li S, et al. Factors associated with clinical remission of skin disease in dermatomyositis. JAMA Dermatol. 2018;154:44–51.CrossRef
6.
He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141–9.CrossRef
7.
Humrich JY, von Spee-Mayer C, Siegert E, et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol. 2019;1(1):e44–54.CrossRef
Metadata
Title
Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
Authors
Miao Miao
Yuhui Li
Bo Huang
Jing He
Zhanguo Li
Publication date
01-10-2020
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 5/2020
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-020-00421-8

Other articles of this Issue 5/2020

Dermatology and Therapy 5/2020 Go to the issue

Original Research

Dermoscopy of Cutaneous Graft-Versus-Host-Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation

Case Report

Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides

Review

Cellular Digital Fibroma: A Comprehensive Review of a CD34-Positive Acral Lesion of the Distal Fingers and Toes

Review

Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis

Original Research

Evaluation of BepanGel Hydrogel Efficacy and Tolerability Using an Abrasive Wound Model in a Within-Person, Single-Center, Randomized, Investigator-Blind Clinical Investigation

Correction

Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits